1. Anti-infection
  2. Bacterial

Tedizolid phosphate (Synonyms: TR-701FA)

Cat. No.: HY-14855B
Handling Instructions

Tedizolid phosphate is a novel oxazolidinone with activity against Gram-positive pathogens.

For research use only. We do not sell to patients.
Tedizolid phosphate Chemical Structure

Tedizolid phosphate Chemical Structure

CAS No. : 856867-55-5

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $88 In-stock
5 mg $80 In-stock
10 mg $140 In-stock
50 mg $500 In-stock
100 mg $770 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Tedizolid phosphate:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Tedizolid phosphate is a novel oxazolidinone with activity against Gram-positive pathogens.

In Vitro

Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP, and is 4-fold more potent than linezolid against PRSP[1].

In Vivo

For mice infected with PSSP type III, the 100% survival rate is achieved with tedizolid phosphate at a minimum total daily dose of 10 mg/kg. Lungs of infected mice treated with tedizolid phosphate show less severe inflammation and edema, as indicated by the mean scores for inflammation and edema[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03009045 Los Angeles Biomedical Research Institute Bone and Joint Infection February 6, 2017 Phase 2
NCT02342418 Amit.Pai|Merck Sharp & Dohme Corp.|Albany College of Pharmacy and Health Sciences Obesity March 2015 Phase 4
NCT02620787 Hartford Hospital|Merck Sharp & Dohme Corp. Diabetes|Wound Infection|Healthy Volunteers February 23, 2016 Phase 1
NCT03217565 Merck Sharp & Dohme Corp. Gram-Positive Infections March 5, 2018 Phase 1
NCT02444234 University of Southern California|Merck Sharp & Dohme Corp. Cystic Fibrosis July 2015 Phase 4
NCT02750761 Merck Sharp & Dohme Corp. Gram-Positive Bacterial Infections May 2, 2016 Phase 1
NCT02276482 Cubist Pharmaceuticals LLC Skin Diseases, Infectious|Skin Diseases, Bacterial March 25, 2015 Phase 3
NCT02991131 Bayer Abscess|Cellulitis|Erysipelas|Wound Infection January 13, 2017
NCT02066402 Bayer|Merck Sharp & Dohme Corp. Bacterial Infections March 4, 2014 Phase 3
NCT02019420 Cubist Pharmaceuticals LLC Pneumonia January 6, 2014 Phase 3
NCT02477514 Merck Sharp & Dohme Corp. Skin Diseases, Bacterial June 2015 Phase 1
NCT01967225 Bayer Skin Diseases, Infectious November 2013 Phase 3
NCT00666601 Trius Therapeutics LLC Healthy April 2008 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.2206 mL 11.1032 mL 22.2064 mL
5 mM 0.4441 mL 2.2206 mL 4.4413 mL
10 mM 0.2221 mL 1.1103 mL 2.2206 mL
Animal Administration
[1]

To induce a systemic S. pneumoniae infection, male ICR mice (weight, 18 to 20 g) are inoculated intraperitoneally with 1 of 4 PRSP isolates (DR9, DR10, DR11, or DR14) suspended in 10% mucin. The suspension contained sufficient bacteria to kill 100% of untreated control mice. At 1 h postinfection, mice receives a single dose of either tedizolid phosphate or linezolid, and survival is assessed daily for 7 days postinfection. Treatments are delivered both orally and intravenously at each of four doses (40 mg/kg of body weight, 13.33 mg/kg, 4.44 mg/kg, and 1.48 mg/kg), with 8 mice per group defined by dose, delivery method, and infecting strain. The 50% effective dose (ED50), i.e., the dose allowing survival of 50% of the infected mice, is calculated for each delivery route using probit analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
M.Wt

450.32

Formula

C₁₇H₁₆FN₆O₆P

CAS No.

856867-55-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 36 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tedizolid phosphate
Cat. No.:
HY-14855B
Quantity: